Esperion Therapeutis.Inc. sell Northland Securities
Start price
16.03.23
/
50%
€1.91
Target price
16.03.24
-
Performance (%)
4.19%
End price
17.03.24
€1.99
Summary
This prediction ended on 17.03.24 with a price of €1.99. With a performance of 4.19%, the SELL prediction by Northland_Securities for Esperion Therapeutis.Inc. was trending in the wrong direction Northland_Securities has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Esperion Therapeutis.Inc. | 4.054% | 4.054% | 63.533% |
| iShares Core DAX® | 0.961% | -2.210% | 12.839% |
| iShares Nasdaq 100 | 2.626% | -1.918% | 38.498% |
| iShares Nikkei 225® | 0.217% | -7.216% | 19.425% |
| iShares S&P 500 | 1.540% | -1.858% | 27.801% |
Comments by Northland_Securities for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Esperion Therapeutics, Inc. (NASDAQ: ESPR) was downgraded by analysts at Northland Securities from a "market perform" rating to an "underperform" rating.
Ratings data for ESPR provided by MarketBeat
In the thread Trading Esperion Therapeutis.Inc.
Die von Northland_Securities gewählte maximale Laufzeit wurde überschritten